Altogether, our study suggests that CD36, by activating glycolysis through Src/PI3K/AKT/ mTOR signaling pathway, could be a critical step in the development and progression of HCC; thus, CD36 may be a novel target for liver cancer therapy. Here, SRC is linked to liver cancer.